Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing therapeutics for anxiety, depression, and addiction, announced participation in the Benzinga Psychedelics Capital Conference on April 13, 2023. CEO
Dr. Tucker aims to showcase Enveric's clinical development strategy, including the upcoming Phase 1 study of lead candidate EB-373 in Australia.
- None.
- None.
CEO
Details of Enveric’s participation are as follows:
Presentation Format: |
Fireside Chat |
Date: |
|
Time: |
|
Location: |
Playbook Stage, Fontainebleau Miami |
Presentation Format: |
Panel |
Title: |
|
Date: |
|
Time: |
|
Location: |
Playbook Stage, Fontainebleau Miami |
During the conference,
About
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” ”expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005386/en/
Investor Relations
(862) 213-1398
dboateng@tiberend.com
Media Relations
(646) 577-8520
cmcdonald@tiberend.com
Source:
FAQ
When is Enveric Biosciences participating in the Benzinga Psychedelics Capital Conference?
What time is the fireside chat featuring Joseph Tucker?
What is the title of the panel discussion Joseph Tucker will join?
Where is the Benzinga Psychedelics Capital Conference being held?
What will be discussed in regard to the Phase 1 study at the conference?
What is the stock symbol for Enveric Biosciences?
